Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Novo Nordisk
So What: Shares have been down the last two days on concerns Bydureon -- a new diabetes drug from Amylin
Now What: This is great news for Novo Nordisk's position in the diabetes market in the U.S. but Europe still looms on the horizon. Some analysts expect European approval for Bydureon in the first half of 2011. This risk from Europe makes me think twice before jumping on Novo Nordisk's stock on a day like today.
Interested in more info on Novo Nordisk? Add it to your watchlist here by clicking here.